Dexamethasone prodrug compositions and uses thereof
The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.
1. An article comprising compound 1:
wherein the article provides controlled release of dexamethasone at 37° C. in 100% bovine serum or at 37° C. in phosphate buffered saline.
2. The article of claim 1 , wherein the compound or dexamethasone is released from the article through surface erosion.
3. The article of claim 1 , wherein the article is formed by a process comprising the steps of: (a) heating the compound to form a melt; and (b) heat molding the melt to form the article.
4. The article of claim 1 , wherein the article is formed by a process comprising the steps of: (a) heating the compound to form a melt; and (b) injection molding the melt to form the article.
5. The article of claim 1 , wherein the article is formed by a process comprising the steps of: (a) heating the compound to form an intermediate glassy state material; and (b) heat extruding the intermediate glassy state material to form the article.
6. The article of claim 1 , wherein the article is formed by a process comprising the steps of: (a) dissolving the compound in a solvent to form a solution; and (b) evaporating the solvent to form the article.
7. The article of claim 6 , wherein step (b) comprises solvent casting to form a film or a fiber.
8. The article of claim 1 , wherein the article is formed by a process comprising the steps of: (a) dissolving the compound in a solvent to form a solution; and (b) electrospinning or electrospraying the solution to form the article.
9. The article of claim 1 , wherein the article is formed by a process comprising the steps of: (a) dissolving the compound in an organic solvent containing a surfactant to form an emulsion; and (b) removing organic solvent from the emulsion to form the article in the shape of a nanoparticle or microparticle.
10. The article of claim 1 , wherein the article is formed by a process comprising the steps of: (a) heating the compound to form a melt; and (b) extruding the melt to form the article.
11. The article of claim 1 , wherein at least 70% (w/w) of the article is Compound 1.
12. The article of claim 1 , wherein at least 90% (w/w) of the article is Compound 1.
13. The article of claim 1 , wherein the article further comprises from 0.1% to 10% (w/w) of one or more additives, wherein the one or more additives are selected from plasticizers, antioxidants, binders, lubricants, radio-opaque agents, and mixtures thereof.
14. The article of claim 1 , wherein the article is a fiber, fiber mesh, woven fabric, non-woven fabric, pellet, cylinder, hollow tube, microparticle, nanoparticle, or shaped article.
15. The article of claim 1 , wherein the article is free of controlled release excipient, free of a crystallization inhibiting excipient, free of a mechanical integrity enhancing excipient, and/or free of a binding excipient.
16. The article of claim 1 , wherein the article has a glassy state.
17. A method of treating an inflammatory disease or disorder in a subject in need thereof, the method comprising administering to the subject the article of claim 1 in an amount sufficient to treat the inflammatory disease or disorder in the subject.
18. The method of claim 17 , wherein the article is administered locally.
19. The method of claim 18 , wherein the article is administered intraocularly.
20. The method of claim 18 , wherein the article is administered into a joint space.
21. The method of claim 17 , wherein the article is a fiber, fiber mesh, woven fabric, non-woven fabric, pellet, cylinder, hollow tube, microparticle, nanoparticle, or shaped article.
22. The method of claim 17 , wherein at least 70% (w/w) of the article is Compound 1.
23. The method of claim 17 , wherein at least 90% (w/w) of the article is Compound 1.
24. The method of claim 17 , wherein the inflammatory disease or disorder is osteoarthritis.
25. The method of claim 18 , wherein the article is locally administered to a site as a coating on the surface of an implantable medical device and the method comprises implanting the medical device into the site.
26. An article comprising compound 6:
wherein the article provides controlled release of dexamethasone at 37° C. in 100% bovine serum or at 37° C. in phosphate buffered saline.
27. The article of claim 26 , wherein the compound or dexamethasone is released from the article through surface erosion.
28. The article of claim 26 , wherein the article is formed by a process comprising the steps of: (a) heating the compound to form a melt; and (b) heat molding the melt to form the article.
29. The article of claim 26 , wherein the article is formed by a process comprising the steps of: (a) heating the compound to form a melt; and (b) injection molding the melt to form the article.
30. The article of claim 26 , wherein the article is formed by a process comprising the steps of: (a) heating the compound to form an intermediate glassy state material; and (b) heat extruding the intermediate glassy state material to form the article.
31. The article of claim 26 , wherein the article is formed by a process comprising the steps of: (a) dissolving the compound in a solvent to form a solution; and (b) evaporating the solvent to form the article.
32. The article of claim 31 , wherein step (b) comprises solvent casting to form a film or a fiber.
33. The article of claim 26 , wherein the article is formed by a process comprising the steps of: (a) dissolving the compound in a solvent to form a solution; and (b) electrospinning or electrospraying the solution to form the article.
34. The article of claim 26 , wherein the article is formed by a process comprising the steps of: (a) dissolving the compound in an organic solvent containing a surfactant to form an emulsion; and (b) removing organic solvent from the emulsion to form the article in the shape of a nanoparticle or microparticle.
35. The article of claim 26 , wherein the article is formed by a process comprising the steps of: (a) heating the compound to form a melt; and (b) extruding the melt to form the article.
36. The article of claim 26 , wherein at least 70% (w/w) of the article is Compound 6.
37. The article of claim 26 , wherein at least 90% (w/w) of the article is Compound 6.
38. The article of claim 26 , wherein the article further comprises from 0.1% to 10% (w/w) of one or more additives, wherein the one or more additives are selected from plasticizers, antioxidants, binders, lubricants, radio-opaque agents, and mixtures thereof.
39. The article of claim 26 , wherein the article is a fiber, fiber mesh, woven fabric, non-woven fabric, pellet, cylinder, hollow tube, microparticle, nanoparticle, or shaped article.
40. The article of claim 26 , wherein the article is free of controlled release excipient, free of a crystallization inhibiting excipient, free of a mechanical integrity enhancing excipient, and/or free of a binding excipient.
41. The article of claim 26 , wherein the article has a glassy state.
42. A method of treating an inflammatory disease or disorder in a subject in need thereof, the method comprising administering to the subject the article of claim 26 in an amount sufficient to treat the inflammatory disease or disorder in the subject.
43. The method of claim 42 , wherein the article is administered locally.
44. The method of claim 43 , wherein the article is administered intraocularly.
45. The method of claim 44 , wherein the article is administered into a joint space.
46. The method of claim 42 , wherein the article is a fiber, fiber mesh, woven fabric, non-woven fabric, pellet, cylinder, hollow tube, microparticle, nanoparticle, or shaped article.
47. The method of claim 42 , wherein at least 70% (w/w) of the article is Compound 6.
48. The method of claim 42 , wherein at least 90% (w/w) of the article is Compound 6.
49. The method of claim 42 , wherein the inflammatory disease or disorder is osteoarthritis.
50. The method of claim 43 , wherein the article is locally administered to a site as a coating on the surface of an implantable medical device and the method comprises implanting the medical device into the site.